Analyst Price Target is $13.60
▲ +357.14% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Century Therapeutics in the last 3 months. The average price target is $13.60, with a high forecast of $24.00 and a low forecast of $5.00. The average price target represents a 357.14% upside from the last price of $2.98.
Current Consensus is
Moderate Buy
The current consensus among 5 contributing investment analysts is to moderate buy stock in Century Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Read More
